Multiple Myeloma: all 3,713 studies
Page 19 of 38. Open to participants first (754), then studies with results posted, then the rest; newest registration first within each.
- A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT05704049Phase 2
- Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid TumorsTerminatedNCT05698888Phase 1
- Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow TransplantationActive, not recruitingNCT05697913Not applicable
- Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Multiple MyelomaStatus unknownNCT05693012
- Elimination of Minimal Residual Disease After TransplantActive, not recruitingNCT05690984Phase 2
- Improving Patient Experience: BMBACompletedNCT05690230Not applicable
- A Rollover Study of CC-122Active, not recruitingNCT05688475Phase 1
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male SubjectsCompletedNCT05679258Phase 1
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple MyelomaActive, not recruitingNCT05675449Phase 1
- Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line TherapyTerminatedNCT05675319Phase 3
- Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT05673967
- Impact of a Health Technology Intervention on Patient Activation in Multiple MyelomaActive, not recruitingNCT05673083
- 89Zr-labeled NY008 PET Imaging in PatientsStatus unknownNCT05655676Early Phase 1
- Clinical Study of the Safety and Efficacy of BCMA CAR-NKStatus unknownNCT05652530Early Phase 1
- Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell DiseasesWithdrawnNCT05647512Phase 1/2
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05646836Phase 1
- To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy SubjectsCompletedNCT05643248Early Phase 1
- A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)TerminatedNCT05641324Phase 1
- A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple MyelomaCompletedNCT05620420
- Home Treatment With Carfilzomib in Patients With Multiple MyelomaCompletedNCT05620238
- CAR-T Cells in the Treatment of Malignant Hematological TumorsStatus unknownNCT05619861Not applicable
- Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom MonitoringActive, not recruitingNCT05587972Not applicable
- Ultra-low-dose Whole-body CT Using AI-based CT Reconstruction in Patients With Multiple MyelomaStatus unknownNCT05577884
- Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05577000Phase 1
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Phase 3
- Study of Teclistamab in Combination in Elderly Patients With Multiple MyelomaActive, not recruitingNCT05572229Phase 2
- A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic MalignanciesCompletedNCT05567887Phase 1
- Doxil/Caelyx BE StudyCompletedNCT05567601Phase 1
- Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell TransplantCompletedNCT05561751Phase 2
- A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05560399Early Phase 1
- A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentActive, not recruitingNCT05556798Phase 1
- Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical TrialActive, not recruitingNCT05556720Phase 3
- Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day; the POMAlternative StudyCompletedNCT05555329Phase 4
- A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Active, not recruitingNCT05552976Phase 3
- Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaStatus unknownNCT05549973Phase 1
- Benefits of Adapted Physical Activity for Chronic Osteoarticular Pain in Patients With Multiple MyelomaStatus unknownNCT05548686Not applicable
- Thrombosis in Patients With Multiple Myeloma in an University Medical CenterCompletedNCT05541978
- Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple MyelomaStatus unknownNCT05536700
- A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05535244Phase 1/2
- Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.Active, not recruitingNCT05527340Phase 2
- High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT05517213Not applicable
- Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialActive, not recruitingNCT05514990Phase 1/2
- Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid MalignanciesWithdrawnNCT05513612Phase 1
- Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and DexamethasoneStatus unknownNCT05509374Phase 2
- Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple MyelomaNo longer availableNCT05503550
- Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT05498545Phase 1
- Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH TrialActive, not recruitingNCT05497804Phase 2
- Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCTStatus unknownNCT05497102Phase 2
- Long-term KRd in Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05495620
- Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCTActive, not recruitingNCT05493800Phase 2
- Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.WithdrawnNCT05493618Phase 1/2
- This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.Status unknownNCT05486975Early Phase 1
- Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple MyelomaStatus unknownNCT05478343Early Phase 1
- Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma PatientsApproved for marketingNCT05463939
- Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple MyelomaNo longer availableNCT05462639
- A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to TreatmentActive, not recruitingNCT05455320Phase 3
- A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple MyelomaStatus unknownNCT05448404Not applicable
- Assessing the Impact of a Financial Navigation Program for Patients With Multiple MyelomaCompletedNCT05448196Not applicable
- CART-38 in Adult AML and MM PatientsTerminatedNCT05442580Phase 1
- Serum NGAL IN Patients With Multiple MyelomaStatus unknownNCT05439538
- Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MMStatus unknownNCT05438394Phase 1
- A Study of DaratumumabActive, not recruitingNCT05438043Phase 3
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomideActive, not recruitingNCT05434689Phase 1/2
- PVd Versus Vd in NDMM Patients With RIStatus unknownNCT05432414Phase 2
- A Study of MCARH109 and MCARH125 in People With Multiple MyelomaActive, not recruitingNCT05431608Phase 1
- A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaStatus unknownNCT05430945Early Phase 1
- Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) PatientsCompletedNCT05428163
- Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple MyelomaTerminatedNCT05427812Phase 1/2
- Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple MyelomaStatus unknownNCT05412329Phase 1
- Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT05411497Phase 1
- Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMMWithdrawnNCT05408026Phase 1/2
- Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in CancerSuspendedNCT05400122Phase 1
- Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Active, not recruitingNCT05396885Phase 2
- A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell TransplantActive, not recruitingNCT05393804Phase 2
- Patient With MMRR Treated With Belantamab Mafotidine on MonotherapyCompletedNCT05393024
- Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL StudyActive, not recruitingNCT05392946Phase 1/2
- Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple MyelomaActive, not recruitingNCT05391750Phase 1
- Evaluation of Whole Body Examination by MRI Integrating the "Zero Time Eco" Sequence (ZTE, Pseudo-CT) for the Detection of Bone Lesions in Multiple Myeloma: Comparison With Pet / CT and Whole Body ScannerStatus unknownNCT05381077Not applicable
- BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT05376345Phase 1
- 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple MyelomaStatus unknownNCT05364177Early Phase 1
- Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaActive, not recruitingNCT05363800Phase 1
- Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell TherapyWithdrawnNCT05362331Not applicable
- Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple MyelomaCompletedNCT05355987Not applicable
- Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)Active, not recruitingNCT05354557Phase 2
- Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and LymphomaActive, not recruitingNCT05346809Phase 2
- Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple MyelomaActive, not recruitingNCT05346198Phase 1
- Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After AutotransplantCompletedNCT05338047Phase 2
- Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple MyelomaActive, not recruitingNCT05336383Phase 2
- The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple MyelomaStatus unknownNCT05331313
- A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple MyelomaStatus unknownNCT05325801Phase 1
- Relevance Evaluation of [68Ga]Ga-PentixaFor for Initial Staging and Detection of Minimal Residual Disease in Multiple Myeloma Patients.WithdrawnNCT05321862Phase 2
- Study of 3D189 in Patients With Hematologic MalignanciesCompletedNCT05320809Phase 1
- Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After TransplantActive, not recruitingNCT05317416Phase 3
- A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 TabletsActive, not recruitingNCT05308654Phase 1
- Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05308225Phase 1/2
- Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.CompletedNCT05306587
- To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MMActive, not recruitingNCT05302648Early Phase 1
- Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.Status unknownNCT05297240
- Study of Novel Regimens in Relapsed or Refractory Multiple MyelomaTerminatedNCT05289492Phase 1
- A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in JapanActive, not recruitingNCT05286229Phase 1